Pneumococcal vaccination in older adults

An update for pharmacists

James Wheeler, Megan L. Ducker

Research output: Contribution to specialist publicationArticle

Abstract

For nearly 50 years, vaccination of high-risk individuals has led to a decrease in the incidence of invasive pneumococcal diseases, such as bacteremia and meningitis. However, for older adult populations, PPSV23 (Pneumovax 23) has not demonstrated consistent protection against pneumococcal pneumonia in clinical trials. Based on recent data from the CAPiTA trial showing both decreased episodes of community acquired pneumonia and a reduction of invasive pneumococcal disease, the CDC’s Advisory Committee on Immunization Practices recently updated the vaccination schedule to include both PPSV23 and PCV13 (Prevnar 13) for those aged <65 years.

Original languageEnglish (US)
Pages54-56
Number of pages3
Volume40
No7
Specialist publicationU.S. Pharmacist
StatePublished - Jul 1 2015

Fingerprint

Pharmacists
Vaccination
Immunization
Pneumococcal Vaccines
Pneumococcal Pneumonia
Advisory Committees
Centers for Disease Control and Prevention (U.S.)
Bacteremia
Meningitis
Pneumonia
Appointments and Schedules
Clinical Trials
Incidence
Population
Pneumovax 23
13-valent pneumococcal vaccine

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this

Pneumococcal vaccination in older adults : An update for pharmacists. / Wheeler, James; Ducker, Megan L.

In: U.S. Pharmacist, Vol. 40, No. 7, 01.07.2015, p. 54-56.

Research output: Contribution to specialist publicationArticle

@misc{a0a9ca69a868470a9daef295c796e6ec,
title = "Pneumococcal vaccination in older adults: An update for pharmacists",
abstract = "For nearly 50 years, vaccination of high-risk individuals has led to a decrease in the incidence of invasive pneumococcal diseases, such as bacteremia and meningitis. However, for older adult populations, PPSV23 (Pneumovax 23) has not demonstrated consistent protection against pneumococcal pneumonia in clinical trials. Based on recent data from the CAPiTA trial showing both decreased episodes of community acquired pneumonia and a reduction of invasive pneumococcal disease, the CDC’s Advisory Committee on Immunization Practices recently updated the vaccination schedule to include both PPSV23 and PCV13 (Prevnar 13) for those aged <65 years.",
author = "James Wheeler and Ducker, {Megan L.}",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
volume = "40",
pages = "54--56",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Pneumococcal vaccination in older adults

T2 - An update for pharmacists

AU - Wheeler, James

AU - Ducker, Megan L.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - For nearly 50 years, vaccination of high-risk individuals has led to a decrease in the incidence of invasive pneumococcal diseases, such as bacteremia and meningitis. However, for older adult populations, PPSV23 (Pneumovax 23) has not demonstrated consistent protection against pneumococcal pneumonia in clinical trials. Based on recent data from the CAPiTA trial showing both decreased episodes of community acquired pneumonia and a reduction of invasive pneumococcal disease, the CDC’s Advisory Committee on Immunization Practices recently updated the vaccination schedule to include both PPSV23 and PCV13 (Prevnar 13) for those aged <65 years.

AB - For nearly 50 years, vaccination of high-risk individuals has led to a decrease in the incidence of invasive pneumococcal diseases, such as bacteremia and meningitis. However, for older adult populations, PPSV23 (Pneumovax 23) has not demonstrated consistent protection against pneumococcal pneumonia in clinical trials. Based on recent data from the CAPiTA trial showing both decreased episodes of community acquired pneumonia and a reduction of invasive pneumococcal disease, the CDC’s Advisory Committee on Immunization Practices recently updated the vaccination schedule to include both PPSV23 and PCV13 (Prevnar 13) for those aged <65 years.

UR - http://www.scopus.com/inward/record.url?scp=84937419388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937419388&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 54

EP - 56

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -